|
Variable
|
B0
|
B1
|
B2
|
B3
|
All patients
|
|---|
|
Number of patients
|
20
|
50
|
45
|
48
|
163
|
|
Leucopoenia
|
|
G 0
|
65 (13)
|
78 (39)
|
68.9 (31)
|
62.5 (30)
|
69.3 (113)
|
|
G 1-2
|
20 (4)
|
20 (10)
|
18.9 (13)
|
25 (12)
|
23.9 (39)
|
|
G 3-4
|
15 (3)
|
2 (1)*
|
2.2 (1)*
|
12.5 (6)
|
6.7 (11)
|
|
Thrombocytopenia
|
|
G 0
|
65 (13)
|
52 (26)
|
62.2 (28)
|
66.7 (32)
|
60.7 (99)
|
|
G 1-2
|
25 (5)
|
38 (19)
|
35.6 (16)
|
16.6 (8)
|
19.4 (48)
|
|
G 3-4
|
10 (2)
|
10 (5)
|
2.2 (1)*
|
16.7 (8)
|
9.8 (16)
|
|
Anemia
|
|
G 0
|
80 (16)
|
96 (48)
|
93.3 (42)
|
97.9 (47)
|
93.9 (153)
|
|
G 1-2
|
15 (3)
|
2 (1)
|
6.6 (3)
|
2.1 (1)
|
5 (8)
|
|
G 3-4
|
5 (1)*
|
2 (1)*
|
0
|
0
|
1.2 (2)*
|
|
Neutropenia
|
|
G 0
|
90 (18)
|
94 (47)
|
100 (45)
|
75 (36)
|
89.6 (146)
|
|
G 1-2
|
5 (1)
|
6 (3)
|
0
|
12.5 (6)
|
6.1 (10)
|
|
G 3-4
|
5 (1)
|
0
|
0
|
12.5 (6)
|
4.3 (7)
|
|
Lymphopenia
|
|
G 0
|
100 (20)
|
92 (46)
|
100 (45)
|
77.1 (37)
|
90.8 (148)
|
|
G 1-2
|
0
|
6 (3)
|
0
|
14.6 (7)
|
6.1 (10)
|
|
G 3-4
|
0*
|
2 (1)*
|
0*
|
8.4 (4)
|
3.1 (5)
|
|
Hepatic
|
|
G 0
|
80 (16)
|
96 (48)
|
95.6 (43)
|
93.8 (45)
|
93.3 (152)
|
|
G 1-2
|
20 (4)
|
2 (1)
|
4.4 (2)
|
4.2 (2)
|
5.5 (9)
|
|
G 3-4
|
0
|
2 (1)
|
0
|
2.1 (1)
|
1.2 (2)
|
- *No grade 4 toxicity was detected. B0: patients failing after radiotherapy completion and before starting adjuvant TMZ; B1: patients failing during the first 6 months of adjuvant TMZ; B2: patients who failed after more than 6 months of therapy; B3: patients who experienced tumor recurrence after a treatment-free interval.
